US FDA Integrated Assessment Roll-Out Expanding By End Of 2021
Executive Summary
All NMEs and original BLAs are expected to adhere to the team-based review approach by the end of the year, with expansion to other application types later.
You may also be interested in...
Complete Response Letters: US FDA Tells Congress Broader Disclosures To Sponsors Could Be ‘Chilling’
A lengthy hearing that addressed everything from Aduhelm to advanced manufacturing serves as the formal kick off of the user fee reauthorization season and offers a preview of many possible FDA reforms that House members could seek to include in the legislation.
US FDA Wants Assessment Of New Drug Review ‘Culture’ Amid Modernization, Other Changes
The New Drug Review Program is seeking a contractor to survey employees on the impact of team culture on performance and overall effectiveness.
US FDA’s New ‘Integrated’ Review Process Starts To Win Over Skeptics, But Industry Still Wants More Details
In an interview with the Pink Sheet, implementation director Rhonda Hearns-Stewart says FDA has modified the template for its 'integrated assessment' of marketing applications in response to feedback from reviewers and sponsors.